# Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

> **NCT00362440** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 9 (actual)

## Conditions studied

- HIV Lipodystrophy

## Interventions

- **DRUG:** Leptin
- **DRUG:** Pioglitazone or metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00362440
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362440, "Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00362440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*